Disease Analysis: Non-Small Cell Lung Cancer (NSCLC)
Author: Ellie Davenport
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Disease Overview
Lung cancer is generally categorized as either small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC). Of these, NSCLC is the most common type of lung cancer, accounting for roughly 85% of all cases. NSCLC can be further divided into non-squamous and squamous NSCLC histologies. Squamous NSCLC refers to patients with squamous cell carcinoma, whereas non-squamous NSCLC includes patients with adenocarcinoma, large cell carcinoma, and other less common subtypes. Incidence of adenocarcinoma and squamous cell carcinoma varies greatly by both geographic region and gender. In general, adenocarcinoma comprises approximately 30–50% of all lung cancer cases, while squamous cell carcinoma accounts for roughly 25–35%.
Latest key takeaways
- Datamonitor Healthcare estimates that in 2018, there were 1.8 million incident cases of non-small cell lung cancer (NSCLC) worldwide, and expects that number to increase to 1.9 million incident cases by 2027. The majority of NSCLC diagnoses (65.4%) worldwide are in males, ranging from 52.9% to 72.1% across regions.
- In the last three years, the number of therapies targeting specific sensitizing mutations in metastatic NSCLC has drastically increased, permanently altering the treatment landscape. Many of the new drugs have shown dramatically increased response rates over the previous standard-of-care therapies. However, given the relatively small percentage of metastatic NSCLC patients presenting with each oncogenic driver, competition is fierce and first-to-market advantage is critical.
- Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1)-targeted monoclonal antibodies for NSCLC are forecast to remain the best-selling class of drugs for this indication. Keytruda was the first PD-1/PD-L1 inhibitor to gain regulatory approval for first-line NSCLC patients without an oncogenic driver and has risen to dominance in this market as label expansions have broadened its target patient population and as late-phase trials have revealed consistently positive data. Furthermore, the commercial potential of this class of drugs will increase over the forecast period as the use of checkpoint inhibitors will likely soon extend beyond the metastatic patient population. Label expansions into the earlier treatment settings may provide an opportunity for the other checkpoint inhibitors to differentiate themselves from Keytruda and carve out a niche in this lucrative market.
- PD-L1 inhibitor Imfinzi’s approval for sequential therapy of locally advanced patients following chemoradiation minimizes direct competition with established immunotherapies and has allowed the drug to secure a modest market share.
- Third-generation EGFR inhibitor Tagrisso is now the first-line standard-of-care treatment for NSCLC patients whose tumors harbor activating EGFR mutations (exon 19 deletion or L858R point mutation). Despite competition from Tarceva, Iressa, Gilotrif, Vizimpro, and Alunbrig, Tagrisso will continue to dominate the EGFR inhibitor market due to continued uptake and a recent label expansion into the adjuvant setting. However, Janssen’s recently initiated Phase III MARIPOSA study of amivantamab in combination with lazertinib is the first head-to-head trial against Tagrisso, and the combination could eventually threaten Tagrisso’s position in the first-line setting.
- Amivantamab and mobocertinib are currently in late-stage development for metastatic NSCLC patients whose tumors harbor an exon 20 insertion mutation in EGFR, a population of patients where currently approved therapies are not effective. Competition will be fierce between these two drugs, and the first therapy to market will likely dominate. However, the relative rarity of this mutation limits the commercial potential of an approval in this patient population, and both therapies are also in development for the treatment of other actionable mutations.
- Alecensa has become the new first-line standard of care for ALK rearrangement-positive NSCLC. The Phase III ALEX study demonstrated superior progression-free survival when treated with Alecensa compared with previous standard of care Xalkori. Alecensa will likely remain the class leader even though it will face competition in the first-line setting from other ALK inhibitors such as Zykadia, Alunbrig, and Lorbrena. Dual ALK/ROS1 inhibitor Lorbrena is also approved in both the first- and second-line settings, but has experienced only modest uptake thus far.
- The ALK inhibitors Rozlytrek and Xalkori are both approved for the treatment of metastatic NSCLC patients whose tumors have a ROS1 rearrangement or fusion. Rozlytrek is also approved as a monotherapy for patients with NTRK+ gene fusions. The combined data from Rozlytrek’s development program compare favorably to the data for Xalkori, particularly in patients with CNS metastases at baseline. ROS1 gene rearrangements are present in 1–2% of NSCLC patients, while NTRK fusions are present in approximately 0.2% of cases.
- The combination of BRAF inhibitor Tafinlar and MEK inhibitor Mekinist has become the standard of care for advanced or metastatic NSCLC with BRAF V600E mutations. However, only 1–2% of NSCLC patients have a BRAF V600E mutation, which limits the combination’s commercial potential.
- Two MET inhibitors, Tabrecta and Tepmetko, have been approved for NSCLC patients with a MET exon 14 skipping mutation in the US and Japan. Both drugs are also in development for MET-amplified NSCLC and for patients with EGFR-mutated, c-MET-amplified NSCLC who have progressed after EGFR inhibitor treatment. Potential label expansions into these treatment settings represent a noteworthy market opportunity. Approximately 1–4% of NSCLC patients have a MET exon 14 skipping mutation.
- Retevmo is the first drug approved for the treatment of patients with RET fusion-positive NSCLC. In the pivotal Phase I/II trial, Retevmo demonstrated efficacy in RET fusion-positive patients and in a subgroup of patients with brain metastases. The confirmatory Phase III LIBRETTO-431 trial is ongoing, and approvals in both Europe and Japan are expected based on the Phase I/II data. However, Retevmo will face competition from RET inhibitor Gavreto, which was recently approved in the US.
- As therapies targeting specific oncogenic drivers have established themselves in metastatic NSCLC, attention has shifted toward mutations that do not yet have targeted therapies. Two notable pipeline examples are KRAS inhibitors sotorasib and adagrasib. Both KRAS inhibitors are being investigated as second-line or later treatments for patients with KRAS G12C-mutant NSCLC, a patient population that was previously thought to be undruggable. This is a significant market opportunity given that approximately 13% of NSCLC patients have KRAS p.G12C mutations.
- As checkpoint inhibitor regimens dominate in the first-line setting for patients without sensitizing mutations, effective treatments for the post-immunotherapy setting remain the largest unmet need within the indication. Treatment for these patients is largely palliative, and patients currently have very limited treatment options. A number of therapies, including Cabometyx, Lenvima, sitravatinib, and tusamitamab ravtansine, are in development for this treatment setting.
- The overall likelihood of approval of a Phase I NSCLC asset is 8.1%, and the average probability a drug advances from Phase III is 37.2%. NSCLC drugs, on average, take 9.1 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
- Key upcoming catalysts for 2021 include top-line results for the Phase III SAPPHIRE study of sitravatinib and Opdivo and the Phase III JAVELIN Lung 100 study of Bavencio, as well as PDUFA dates for amivantamab and adagrasib.
CONTENTS
12 OVERVIEW
12 Latest key takeaways
14 DISEASE BACKGROUND
14 Definition
14 Risk factors
15 Symptoms
16 Screening
16 Diagnosis
16 Prognosis
17 Patient segmentation
19 TREATMENT
19 Early-stage NSCLC (Stage I–II; all subtypes)
19 Advanced NSCLC (Stage IIIa–IIIc; all subtypes)
19 Metastatic NSCLC: molecular profiling
20 Metastatic NSCLC: EGFR+
21 Metastatic NSCLC: EGFR+, second line
22 Metastatic NSCLC: KRAS G12C mutation
22 Metastatic NSCLC: ALK+
23 Metastatic NSCLC: ROS1+
24 Metastatic NSCLC: BRAF V600E mutation
25 Metastatic NSCLC: MET exon 14 skipping
26 Metastatic NSCLC: RET+
27 Metastatic NSCLC: NTRK+
28 Metastatic NSCLC: PD-L1+ (≥50%)
29 Metastatic NSCLC: PD-L1+ (≥1–49%)
30 Metastatic NSCLC: all other
31 Metastatic NSCLC: maintenance therapy
32 Metastatic NSCLC: all other second line or later
34 EPIDEMIOLOGY
34 Incidence methodology
37 Prevalence of common non-small cell lung cancer biomarkers
39 MARKETED DRUGS
50 PIPELINE DRUGS
78 KEY REGULATORY EVENTS
78 Amgen Strikes Early-Access Deal In England For Lung Cancer Drug Lumakras
78 Mobocertinib, Asciminib & Surufatinib Among Latest New Filings In EU
78 More PD-1/L1 Inhibitor Adjuvant Submissions
79 Foundation Medicine Obtains FDA Approval For Non-Small Cell Lung Cancer Companion Diagnostic
79 Mirati Marks Another Milestone With Adagrasib
79 Approvals Boost AstraZeneca’s China Cancer Presence
79 NICE Says Yes To Tecentriq For NSCLC
80 Guardant Health Receives FDA Companion Diagnostic Nod
80 Amgen Wins World-First Lumakras Approval, Faces Challenge Of COVID-Era Launch
80 New Approval Strengthens Top Spot For AstraZeneca’s Tagrisso
81 China Biotechs Race To Get First Global IO Green Light Within Months
81 J&J’s Rybrevant May Find Limited Uptake Outside Academic Centers
81 Takeda Touts Mobocertinib Mechanism
82 UK Pips EU To The Post With ‘Project Orbis’ Approval For Tagrisso
82 China Inc. Shines In Latest Batch Of Approvals
82 Positive CHMP Opinion For Tecentriq
82 US FDA Grants Full Approval For Pfizer’s Lorbrena
83 Latecomer Libtayo Wins Coveted First-Line NSCLC Monotherapy Indication
83 Five New EU Filings Leave Starting Blocks At EMA
83 EMD Serono’s Tepmetko Is 6th Novel RTOR Approval
84 Takeda’s Alunbrig Receives Japan Approval For NSCLC
84 World-First Nod For Yuhan’s Lung Cancer Drug, In Korea
84 AstraZeneca On Tagrisso’s Milestone Advance Into Adjuvant Lung Cancer
84 Tepotinib Among Latest EU Filings
85 Lilly’s Multi-Tumor Treatment Retsevmo Closer To EU Approval
85 Keeping Track: J&J Amivantamab Submitted
85 Oncology, Rare Disease Drugs Dominate New China Approvals
85 Imfinzi Gains Four-Week, Fixed-Dose Regimen
86 Real-Time Oncology Review Welcomes Lorbrena
86 Routine UK Funding OKd For Tagrisso In First & Second-Line NSCLC
86 FDA OKs Blueprint/Roche’s Gavreto As Rival To Lilly’s Retevmo
88 PROBABILITY OF SUCCESS
89 LICENSING AND ASSET ACQUISITION DEALS
89 Hunger Game: Hengrui Hunts New Cancer Drug With $200m BeyondSpring Tie-Up
89 Processa Licenses Global Rights For Ocuphire’s RX-3117
89 GSK Spends Heavily On iTeos’ TIGIT To Build A New IO Cornerstone
89 Innovent Acquires Chinese Rights To AnHeart’s Taletrectinib
90 Bristol Pays Out $200m For Agenus’ Preclinical Bispecific TIGIT
90 Sorrento Acquires Abivertinib Partner ACEA
90 MD Anderson Inks New Cancer Collaboration With Mirati
91 TRIGR, Elpiscience Partner On Cancer Immunotherapy In China
91 Bayer Enters CAR-T Space With Atara Pact
91 Merck Pays $2.75bn To Access VelosBio’s ROR1-Targeting ADCs
91 AnHeart Acquires Two More Oncology Assets From Daiichi
93 CLINICAL TRIAL LANDSCAPE
94 Sponsors by status
95 Sponsors by phase
96 Recent events
104 DRUG ASSESSMENT MODEL
104 EGFR inhibitors
106 ROS1 and NTRK gene fusions
106 ALK inhibitors
107 KRAS inhibitors
108 RET inhibitors
108 BRAF inhibitors
109 PARP inhibitors
109 MET inhibitors
110 PD-1/PD-L1 inhibitors
111 TIGIT inhibitor
112 Microtubule inhibitors
112 Folate analog metabolic inhibitor
112 VEGF inhibitors
113 Interleukin 1b antagonist
113 Post-immunotherapy
115 MARKET DYNAMICS
116 FUTURE TRENDS
116 Keytruda is forecast to remain the leading immunotherapy approved for NSCLC
116 Checkpoint inhibitors are expected to move into earlier stages of NSCLC
117 Approvals and subsequent uptake of new therapies in the post-immunotherapy setting will contribute significantly to growth in the NSCLC market
117 Alecensa is expected to continue leading the ALK inhibitor class due to strong results in the first-line setting, despite potential competition
118 Tagrisso will remain the best-selling EGFR inhibitor due to continued uptake in the first-line setting and a label expansion into the adjuvant setting
118 New EGFR inhibitors will address the EGFR exon 20 insertion mutation, which is associated with poor response to current treatments
119 The approval and uptake of MET inhibitors is expected to address unmet needs in patients with exon 14 skipping mutations
119 Recent approvals and subsequent uptake of therapies targeting new mutational drivers will support growth in the NSCLC
market over the forecast period
119 Generic or biosimilar erosion of key brands will have minimal impact on growth
121 CONSENSUS FORECASTS
128 RECENT EVENTS AND ANALYST OPINION
128 Libtayo for NSCLC (September 19, 2021)
129 Rybrevant for NSCLC (September 19, 2021 and September 17, 2021)
130 Enhertu for NSCLC (September 18, 2021)
132 Ilaris for NSCLC (September 17, 2021)
133 Imfinzi for NSCLC (September 17, 2021)
135 Imfinzi for NSCLC (September 9, 2021)
136 Libtayo for NSCLC (August 5, 2021)
138 Plinabulin for NSCLC (August 4, 2021)
139 LN-145 for NSCLC (June 29, 2021)
141 Iressa for NSCLC (June 6, 2021)
143 Tecentriq for NSCLC (June 6, 2021)
145 CLN-081 for NSCLC (June 4, 2021)
147 DZD9008 for NSCLC (June 4, 2021)
148 Imfinzi for NSCLC (June 4, 2021)
150 Keytruda for NSCLC (June 4, 2021)
151 Lumakras for NSCLC (June 4, 2021)
152 Patritumab Deruxtecan for NSCLC (June 4, 2021)
153 Ameile for NSCLC (May 19, 2021)
155 Multiple Drugs for NSCLC (May 19, 2021)
156 TAK-788 for NSCLC (May 19, 2021)
157 Opdivo for NSCLC (April 10, 2021)
159 Poziotinib for NSCLC (April 10, 2021)
160 Telisotuzumab Vedotin for NSCLC (April 10, 2021)
162 Tecentriq for NSCLC (March 21, 2021)
163 Ilaris for NSCLC (March 9, 2021)
165 Keytruda for NSCLC (January 29, 2021)
166 Repotrectinib for NSCLC (January 29, 2021)
168 AMG 510 for NSCLC (January 28, 2021)
170 Amivantamab for NSCLC (January 28, 2021)
172 TAK-788 for NSCLC (January 28, 2021)
174 Bintrafusp Alfa for NSCLC (January 19, 2021)
175 Poziotinib for NSCLC (December 22, 2020)
177 Keytruda for NSCLC (November 9, 2020)
178 Nerlynx for NSCLC (November 5, 2020)
180 Vopratelimab for NSCLC (November 2, 2020)
182 MRTX849 for NSCLC (October 25, 2020)
183 MK-1308 for NSCLC (October 16, 2020)
185 Opdivo for NSCLC (October 7, 2020)
186 AMG 510 for NSCLC (October 5, 2020)
187 Keytruda for NSCLC (September 21, 2020)
189 Libtayo for NSCLC (September 21, 2020)
191 AMG 510 for NSCLC (September 20, 2020)
193 Amivantamab for NSCLC (September 20, 2020)
194 Lorbrena for NSCLC (September 19, 2020)
196 Tagrisso for NSCLC (September 19, 2020)
198 U3-1402 for NSCLC (September 18, 2020)
200 CLN-081 for NSCLC (September 17, 2020)
201 Lenvima for NSCLC (September 17, 2020)
203 KEY UPCOMING EVENTS
206 KEY OPINION LEADER INSIGHTS
207 UNMET NEEDS
208 BIBLIOGRAPHY
211 APPENDIX
LIST OF FIGURES
36 Figure 1: Trends in incident cases of NSCLC, 2018–27
50 Figure 2: Overview of pipeline drugs for NSCLC in the US
50 Figure 3: Pipeline drugs for NSCLC, by company
51 Figure 4: Pipeline drugs for NSCLC, by drug type
51 Figure 5: Pipeline drugs for NSCLC, by classification
88 Figure 6: Probability of success in the NSCLC pipeline
93 Figure 7: Clinical trials in NSCLC
93 Figure 8: Top 10 drugs for clinical trials in NSCLC
94 Figure 9: Top 10 companies for clinical trials in NSCLC
94 Figure 10: Trial locations in NSCLC
95 Figure 11: NSCLC trials status
96 Figure 12: NSCLC trials sponsors, by phase
104 Figure 13: Datamonitor Healthcare’s drug assessment summary for NSCLC
115 Figure 14: Market dynamics in NSCLC
116 Figure 15: Future trends in NSCLC
129 Figure 16: Libtayo for NSCLC (September 19, 2021): Phase III – EMPOWER-Lung 3
132 Figure 17: Enhertu for NSCLC (September 18, 2021): Phase II – DESTINY-Lung01
135 Figure 18: Imfinzi for NSCLC (September 17, 2021): Phase II – COAST
136 Figure 19: Imfinzi for NSCLC (September 9, 2021): Phase III – POSEIDON (w/Tremelimumab)
138 Figure 20: Libtayo for NSCLC (August 5, 2021): Phase III – EMPOWER-Lung 3
139 Figure 21: Plinabulin for NSCLC (August 4, 2021): Phase III – DUBLIN-3
141 Figure 22: LN-145 for NSCLC (June 29, 2021): Phase II – IOV-COM-202
143 Figure 23: Iressa for NSCLC (June 6, 2021): Phase III – IMPACT, WJOG6410L (Japan)
145 Figure 24: Tecentriq for NSCLC (June 6, 2021): Phase III – IMpower 010 (PD-L1 Selected, Post-Adjuvant)
147 Figure 25: CLN-081 for NSCLC (June 4, 2021): Phase I/IIa – EGFR Exon 20 Mut.
150 Figure 26: Imfinzi for NSCLC (June 4, 2021): Phase III – PACIFIC
155 Figure 27: Ameile for NSCLC (May 19, 2021): Phase III – AENEAS (China)
157 Figure 28: TAK-788 for NSCLC (May 19, 2021): Phase I/II – EXCLAIM
159 Figure 29: Opdivo for NSCLC (April 10, 2021): Phase III – CheckMate-816
162 Figure 30: Telisotuzumab Vedotin for NSCLC (April 10, 2021): Phase II – c-Met+
165 Figure 31: Ilaris for NSCLC (March 9, 2021): Phase III – CANOPY-2
166 Figure 32: Keytruda for NSCLC (January 29, 2021): Phase III – KEYNOTE-598
168 Figure 33: Repotrectinib for NSCLC (January 29, 2021): Phase I/II – TRIDENT-1
170 Figure 34: AMG 510 for NSCLC (January 28, 2021): Phase I/II – CodeBreaK 100
172 Figure 35: Amivantamab for NSCLC (January 28, 2021): Phase I – CHRYSALIS (Advanced NSCLC)
174 Figure 36: TAK-788 for NSCLC (January 28, 2021): Phase I/II – EXCLAIM
177 Figure 37: Poziotinib for NSCLC (December 22, 2020): Phase II – ZENITH20 (EGFR or HER2 Exon 20 Mut.)
180 Figure 38: Nerlynx for NSCLC (November 5, 2020): Phase II – SUMMIT Basket (HER2mut, EGFRmut)
182 Figure 39: Vopratelimab for NSCLC (November 2, 2020): Phase II – EMERGE (w/Ipilimumab)
185 Figure 40: MK-1308 for NSCLC (October 16, 2020): Phase I/II – w/Pembrolizumab
186 Figure 41: Opdivo for NSCLC (October 7, 2020): Phase III – CheckMate-816
189 Figure 42: Keytruda for NSCLC (September 21, 2020): Phase III – KEYNOTE-024 (1L Monotherapy)
191 Figure 43: Libtayo for NSCLC (September 21, 2020): Phase III – EMPOWER-Lung 1 (1st Line)
193 Figure 44: AMG 510 for NSCLC (September 20, 2020): Phase I/II – CodeBreaK 100
196 Figure 45: Lorbrena for NSCLC (September 19, 2020): Phase III – CROWN (vs. Crizotinib)
198 Figure 46: Tagrisso for NSCLC (September 19, 2020): Phase III – ADAURA
200 Figure 47: U3-1402 for NSCLC (September 18, 2020): Phase I – A-U102
203 Figure 48: Key upcoming events in NSCLC (one of four)
204 Figure 49: Key upcoming events in NSCLC (two of four)
204 Figure 50: Key upcoming events in NSCLC (three of four)
205 Figure 51: Key upcoming events in NSCLC (four of four)
LIST OF TABLES
17 Table 1: Five-year survival rates of lung cancer, by stage at diagnosis
18 Table 2: Non-small cell lung cancer staging and corresponding TNM classifications
21 Table 3: Preferred branded first-line treatment regimens for patients with Stage IV EGFR+ NSCLC
22 Table 4: Preferred branded treatment regimens for patients who progress on first- and second-generation EGFR TKIs
23 Table 5: Preferred branded first- and second-line treatment regimens for patients with Stage IV ALK+ NSCLC
24 Table 6: Preferred treatment regimens for patients with Stage IV ROS1+ NSCLC
25 Table 7: Preferred treatment regimens for patients with Stage IV BRAF V600E mutated NSCLC
26 Table 8: Preferred treatment regimens for patients with Stage IV NSCLC and a MET exon 14 skipping mutation
27 Table 9: Preferred treatment regimens for patients with Stage IV RET+ NSCLC
28 Table 10: Preferred treatment regimens for patients with Stage IV NTRK+ NSCLC
29 Table 11: Preferred branded first-line treatment regimens for patients with advanced NSCLC and PD-L1+ TPS ≥50%
30 Table 12: Preferred branded first-line treatment regimens for patients with advanced NSCLC and PD-L1+ TPS ≥1–49%
31 Table 13: Preferred branded first-line treatment regimens for patients with advanced NSCLC
33 Table 14: Preferred branded second-line or later treatment regimens for patients with metastatic NSCLC
35 Table 15: Incident cases of NSCLC, 2018–27
37 Table 16: Incident cases of NSCLC, by gender, 2018
40 Table 17: Marketed drugs for NSCLC
52 Table 18: Pipeline drugs for NSCLC in the US
122 Table 19: Historical global sales, by drug ($m), 2016–20
125 Table 20: Forecasted global sales, by drug ($m), 2021–25
128 Table 21: Libtayo for NSCLC (September 19, 2021)
130 Table 22: Rybrevant for NSCLC (September 19, 2021 and September 17, 2021)
131 Table 23: Enhertu for NSCLC (September 18, 2021)
133 Table 24: Ilaris for NSCLC (September 17, 2021)
134 Table 25: Imfinzi for NSCLC (September 17, 2021)
135 Table 26: Imfinzi for NSCLC (September 9, 2021)
137 Table 27: Libtayo for NSCLC (August 5, 2021)
138 Table 28: Plinabulin for NSCLC (August 4, 2021)
140 Table 29: LN-145 for NSCLC (June 29, 2021)
142 Table 30: Iressa for NSCLC (June 6, 2021)
143 Table 31: Tecentriq for NSCLC (June 6, 2021)
146 Table 32: CLN-081 for NSCLC (June 4, 2021)
148 Table 33: DZD9008 for NSCLC (June 4, 2021)
149 Table 34: Imfinzi for NSCLC (June 4, 2021)
151 Table 35: Keytruda for NSCLC (June 4, 2021)
152 Table 36: Lumakras for NSCLC (June 4, 2021)
153 Table 37: Patritumab Deruxtecan for NSCLC (June 4, 2021)
154 Table 38: Ameile for NSCLC (May 19, 2021)
155 Table 39: Multiple Drugs for NSCLC (May 19, 2021)
156 Table 40: TAK-788 for NSCLC (May 19, 2021)
158 Table 41: Opdivo for NSCLC (April 10, 2021)
159 Table 42: Poziotinib for NSCLC (April 10, 2021)
160 Table 43: Telisotuzumab Vedotin for NSCLC (April 10, 2021)
163 Table 44: Tecentriq for NSCLC (March 21, 2021)
164 Table 45: Ilaris for NSCLC (March 9, 2021)
165 Table 46: Keytruda for NSCLC (January 29, 2021)
167 Table 47: Repotrectinib for NSCLC (January 29, 2021)
168 Table 48: AMG 510 for NSCLC (January 28, 2021)
171 Table 49: Amivantamab for NSCLC (January 28, 2021)
173 Table 50: TAK-788 for NSCLC (January 28, 2021)
175 Table 51: Bintrafusp Alfa for NSCLC (January 19, 2021)
176 Table 52: Poziotinib for NSCLC (December 22, 2020)
178 Table 53: Keytruda for NSCLC (November 9, 2020)
179 Table 54: Nerlynx for NSCLC (November 5, 2020)
181 Table 55: Vopratelimab for NSCLC (November 2, 2020)
182 Table 56: MRTX849 for NSCLC (October 25, 2020)
184 Table 57: MK-1308 for NSCLC (October 16, 2020)
185 Table 58: Opdivo for NSCLC (October 7, 2020)
187 Table 59: AMG 510 for NSCLC (October 5, 2020)
188 Table 60: Keytruda for NSCLC (September 21, 2020)
190 Table 61: Libtayo for NSCLC (September 21, 2020)
192 Table 62: AMG 510 for NSCLC (September 20, 2020)
194 Table 63: Amivantamab for NSCLC (September 20, 2020)
195 Table 64: Lorbrena for NSCLC (September 19, 2020)
197 Table 65: Tagrisso for NSCLC (September 19, 2020)
199 Table 66: U3-1402 for NSCLC (September 18, 2020)
201 Table 67: CLN-081 for NSCLC (September 17, 2020)
202 Table 68: Lenvima for NSCLC (September 17, 2020)
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Chemotherapy-Induced Anemia 
Sign up to the